AU2020208909B2 - Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy - Google Patents

Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy Download PDF

Info

Publication number
AU2020208909B2
AU2020208909B2 AU2020208909A AU2020208909A AU2020208909B2 AU 2020208909 B2 AU2020208909 B2 AU 2020208909B2 AU 2020208909 A AU2020208909 A AU 2020208909A AU 2020208909 A AU2020208909 A AU 2020208909A AU 2020208909 B2 AU2020208909 B2 AU 2020208909B2
Authority
AU
Australia
Prior art keywords
residue
polypeptide
mutated
substituted
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020208909A
Other languages
English (en)
Other versions
AU2020208909A1 (en
Inventor
Ignacio ANEGON
Carole GUILLONNEAU
Erwan Mortier
Agnès QUEMENER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Nantes Université
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite de Nantes
Publication of AU2020208909A1 publication Critical patent/AU2020208909A1/en
Assigned to INSERM (Institut National de la Santé et de la Recherche Médicale), NANTES UNIVERSITÉ reassignment INSERM (Institut National de la Santé et de la Recherche Médicale) Amend patent request/document other than specification (104) Assignors: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Nantes
Application granted granted Critical
Publication of AU2020208909B2 publication Critical patent/AU2020208909B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2020208909A 2019-01-15 2020-01-15 Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy Active AU2020208909B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305046.5 2019-01-15
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
AU2020208909A1 AU2020208909A1 (en) 2021-07-29
AU2020208909B2 true AU2020208909B2 (en) 2025-02-20

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020208909A Active AU2020208909B2 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy

Country Status (13)

Country Link
US (1) US12466866B2 (https=)
EP (1) EP3911670B1 (https=)
JP (2) JP7645185B2 (https=)
KR (1) KR20210121077A (https=)
CN (1) CN113508129B (https=)
AU (1) AU2020208909B2 (https=)
BR (1) BR112021013944A8 (https=)
CA (1) CA3126741A1 (https=)
ES (1) ES3011707T3 (https=)
IL (1) IL284868B2 (https=)
MX (1) MX2021008525A (https=)
SG (1) SG11202107606VA (https=)
WO (1) WO2020148338A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148338A1 (en) * 2019-01-15 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115252764A (zh) * 2022-08-09 2022-11-01 南方医科大学 一种白介素在制备治疗急性髓系白血病的药物中的应用
EP4653869A1 (en) * 2024-05-21 2025-11-26 Nantes Université Molecules mimicking interleukin 34 bone regulation activity based on the binding of il-34 to bone morphogenetic proteins, method of screening and pharmaceutical composition
WO2025254101A1 (ja) * 2024-06-04 2025-12-11 国立大学法人北海道大学 自己マクロファージによる肝線維症の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012451A2 (en) * 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
EP1935427B1 (en) 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EA031470B1 (ru) 2013-03-15 2019-01-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
EA029661B1 (ru) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
US10155025B2 (en) * 2014-07-17 2018-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34
HK1249016A1 (zh) * 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
CN106084030B (zh) * 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法
WO2020148338A1 (en) * 2019-01-15 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012451A2 (en) * 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BO WANG ET AL: "Integrative genomic analyses of a novel cytokine, interleukin-34 and its potential role in cancer prediction", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 35, no. 1, 12 November 2014 (2014-11-12), GR, pages 92 - 102 *

Also Published As

Publication number Publication date
BR112021013944A8 (pt) 2023-02-07
IL284868B1 (en) 2025-05-01
US20220098264A1 (en) 2022-03-31
CA3126741A1 (en) 2020-07-23
EP3911670B1 (en) 2024-12-25
JP2025000723A (ja) 2025-01-07
EP3911670A1 (en) 2021-11-24
KR20210121077A (ko) 2021-10-07
EP3911670C0 (en) 2024-12-25
IL284868A (en) 2021-08-31
ES3011707T3 (en) 2025-04-08
CN113508129A (zh) 2021-10-15
CN113508129B (zh) 2025-02-18
IL284868B2 (en) 2025-09-01
JP7645185B2 (ja) 2025-03-13
JP2022517029A (ja) 2022-03-03
WO2020148338A1 (en) 2020-07-23
BR112021013944A2 (https=) 2021-11-21
MX2021008525A (es) 2021-11-12
AU2020208909A1 (en) 2021-07-29
US12466866B2 (en) 2025-11-11
SG11202107606VA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
AU2020208909B2 (en) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
JP7673272B2 (ja) キメラ受容体及びその使用方法
US20250011461A1 (en) Human mesothelin chimeric antigen receptors and uses thereof
US20170274014A1 (en) Combinations of low, immune enhancing, doses of mtor inhibitors and cars
JP2017528433A (ja) 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
KR20170037626A (ko) 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
CN114269375A (zh) 抗cd38抗体和配制品
WO2015178746A1 (ko) Pd-l1 융합 단백질 및 이의 용도
KR20160098259A (ko) 인간 메조텔린 키메라 항원 수용체 및 그의 용도
US20250034230A1 (en) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
RU2851193C2 (ru) Мутантный полипептид интерлейкина-34 (IL-34) и его применение в терапии
WO2025210175A1 (en) Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
HK40117228A (zh) 用nk细胞和多特异性接合子治疗癌症
I Sakkas et al. Systemic sclerosis: from pathogenesis towards targeted immunotherapies
BR112020025048A2 (pt) Receptores de antígeno quimérico de bcma e usos dos mesmos
HK1224332B (en) Human mesothelin chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): UNIVERSITE DE NANTES; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: NANTES UNIVERSITE

Free format text: FORMER NAME(S): UNIVERSITE DE NANTES; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

FGA Letters patent sealed or granted (standard patent)